Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc (NQ: BEAM )

23.76 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 628
Open 23.76
Bid (Size) 23.65 (1)
Ask (Size) 24.24 (1)
Prev. Close 23.76
Today's Range 23.76 - 23.76
52wk Range 22.70 - 54.30
Shares Outstanding 79,199,501
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Stocks Cathie Wood Is Buying That Should Be on Your List, Too
Cathie Wood is loading up on these healthcare stocks. 
Via The Motley Fool
2 Cutting-Edge Gene-Editing Stocks That You Don't Want to Miss
The gene-editing market is moving fast, and it pays to get to know some of these companies. 
Via The Motley Fool

Performance

YTD
-36.33%
-36.33%
1 Month
+2.37%
+2.37%
3 Month
-25.68%
-25.68%
6 Month
-22.20%
-22.20%
1 Year
-48.97%
-48.97%

More News

Read More
Here's the 1 Cathie Wood Stock Most Likely to Turn $100,000 Into $1 Million Over the Next 20 Years
Via The Motley Fool
This Cathie Wood Stock Is Down 40% in 2023. Here's Why She's Still Buying It.
Via The Motley Fool
Cathie Wood's Buying These 3 Stocks Hand Over Fist
Via The Motley Fool
4 Analysts Have This to Say About Beam Therapeutics
Via Benzinga
2 Supercharged Growth Stocks That Could Make You Richer
Via The Motley Fool
Beam Therapeutics Presents Preclinical Data Highlighting Utility of BEAM-302 to Correct an Alpha-1 Antitrypsin (AAT) Deficiency Disease-Causing Mutation
From Beam Therapeutics
Via GlobeNewswire
Cathie Wood's Ark Invest Keeps Shedding Shopify Nvidia Shares, Loads Up On Spotify Stock
Via Benzinga
Beam Therapeutics' Role In Gene-Editing 2.0 Revolution: First U.S. Patient Treated With Base-Edited Cell Therapy
Via Benzinga
Beam Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of BEAM-201 in Relapsed, Refractory T-ALL/T-LL
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics to Participate in Upcoming September Investor Conferences
From Beam Therapeutics
Via GlobeNewswire
Why Is Apellis Pharmaceuticals Stock Trading Lower Today?
Via Benzinga
3 Cathie Wood Stocks With Parabolic Growth Potential, According to Wall Street
Via The Motley Fool
Got $200? 3 Growth Stocks to Buy That Could Double Your Money
Via The Motley Fool
Cathie Wood's Ark Invest Sells More Tesla Stock — Acquires Shares Of Flying Taxi Company
Via Benzinga
Cathie Wood's Ark Invest Sells $2.15M Of Tesla Shares Despite Own Bullish Projections
Via Benzinga
Credit Suisse Maintains Neutral Rating for Beam Therapeutics: Here's What You Need To Know
Via Benzinga
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial Results
From Beam Therapeutics
Via GlobeNewswire
3 Pharma Stocks That AI is Loving in July
Via InvestorPlace
Verve Therapeutics Gains 20.74% In June as Ark Funds Invest
Via MarketBeat
Here's the Secret Behind Cathie Wood's Latest Moneymaking Strategy
Via The Motley Fool
Cathie Wood Is Buying This Biotech Stock Like Wildfire, But Should You?
Via The Motley Fool
Beam Therapeutics to Participate in Upcoming May Investor Conferences
From Beam Therapeutics
Via GlobeNewswire
Cathie Wood Is Loading Up on These 3 Stocks Down 70% or More. Should You?
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.